Share |
News

Verisante Announces US Stock Symbol and Participation with Standard & Poors Market Access Program


January 25, 2011 at 7:53 pm

Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTC: VRSEF.PK) (the “Company” or “Verisante”) announced today that its Company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's MarketScope Advisor. 
Information to be made available through this program includes Verisante’s share price, volume, dividends, shares outstanding, company financial position, and earnings.  Standard & Poor's MarketScope Advisor is an Internet-based research engine used by more than 100,000 investment advisors.  A public version of the site is available at www.marketscope.com

In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors.  As part of the program, a full description of Verisante will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in up to 38 states under their Blue Sky Laws.  

As of the market opening on January 24, 2011, Verisante was listed on the OTC Pink Sheets under the stock symbol VRSEF.

“As Verisante begins to lay the groundwork for US regulatory approval of its technology for early detection of cancer, it will become increasingly important for Company information to be readily available in the US and to have access to the US capital markets,” said Thomas Braun, President and CEO. 

About Verisante

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers.

About the BC Cancer Agency

The BC Cancer Agency, an agency of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer, and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British

Columbia by working with community partners to deliver a range of oncology services, including
prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. The BC Cancer Foundation raises funds to support research and enhancements to patient care at the BC Cancer Agency. www.bccancer.bc.ca

About The Skin Care Centre at Vancouver General Hospital

The Skin Care Centre at VGH is affiliated with the UBC Department of Dermatology and Skin Sciences. It is a national centre of excellence uniting clinical care, research, and education. The Centre sees over 20,000 patients annually in general and subspecialty dermatology clinics, and runs the country's busiest phototherapy centre. A critical component of the Skin Care Centre at VGH is its comprehensive and aggressive program dedicated to exploring all aspects of skin cancer, encompassing treatment, clinical, and basic science research.  http://www.skincarecentre.ca/

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information contact:

Verisante Technology, Inc.
Thomas Braun, President & CEO   
Telephone: 1-877-605-0507

Email: info@verisante.com
Website:  www.verisante.com

Standard and Poor’s Customer Contact:
Richard Albanese
212 438-3647
richard_albanese@standardandpoors.com

Standard and Poor’s Media Relations Contact:
Michael Privitera
212 438-6679
michael_privitera@standardandpoors.com

Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top